There is no single drug that protects premature babies from infection at birth — there are several, each targeting a different threat, and the landscape is changing fast. For Respiratory Syncytial Virus, the leading cause of infant hospitalization, two FDA-approved monoclonal antibodies now exist: Beyfortus (nirsevimab) and Enflonsia (clesrovimab). Meanwhile, a preclinical drug called Rytvela is showing remarkable promise at preventing preterm birth itself by calming the inflammatory cascade that triggers early labor, and an inhaled form of GM-CSF may one day prime a newborn’s lungs against bacterial pneumonia within hours of delivery. The old approach — blanketing every premature infant with broad-spectrum antibiotics — is increasingly recognized as a blunt instrument with lasting consequences.
For families navigating dementia care, this topic might seem distant, but it is not. Premature birth and early-life infection have been linked in emerging research to long-term neurodevelopmental outcomes, and the immune disruptions that begin in a NICU can ripple across a lifetime. Understanding how medicine is learning to protect the most vulnerable brains at their most vulnerable moment matters for anyone who cares about brain health across the lifespan. This article covers the RSV antibodies now in clinical use, the experimental drugs in the pipeline, the risks of the antibiotics currently given to nearly all preemies, and what all of it means for the developing brain.
Table of Contents
- Which Drugs Protect Premature Babies From RSV Infection at Birth?
- Maternal Vaccination — Can Protection Start Before Birth?
- Rytvela — A Drug That Could Prevent Preterm Birth Itself
- Inhaled GM-CSF — Training Newborn Lungs to Fight Bacterial Pneumonia
- The Hidden Cost of Antibiotics in the NICU
- Why Neonatal Infection Protection Matters for Lifelong Brain Health
- What Comes Next for Neonatal Infection Prevention
- Conclusion
- Frequently Asked Questions
Which Drugs Protect Premature Babies From RSV Infection at Birth?
The most immediate and well-documented threat to premature infants is Respiratory Syncytial Virus. Babies born at or before 30 weeks’ gestation face roughly three times the RSV hospitalization rate of full-term infants, and their underdeveloped lungs make even a mild infection potentially catastrophic. Beyfortus (nirsevimab), an FDA-approved monoclonal antibody, has become the frontline defense. In clinical trials involving 1,453 preterm infants born between 29 and 35 weeks gestational age, nirsevimab demonstrated 83.2% efficacy against RSV-associated hospitalization. Only 0.3% of infants who received the drug were hospitalized, compared with 1.5% in the standard-care group. As of March 2026, administration of nirsevimab has been extended through April 30, 2026, due to continued RSV activity, according to the North Carolina Department of Health and Human Services. A second option arrived in June 2025 when the FDA approved Enflonsia (clesrovimab), developed by Merck.
Enflonsia uses a single 105 mg dose — the same regardless of an infant’s weight — and provides approximately five months of protection, enough to cover a full RSV season. In its Phase 3 SMART trial, which specifically enrolled early preterm infants born before 29 weeks as well as moderate preterm infants born between 29 and 35 weeks, Enflonsia reduced RSV hospitalizations by 84.3%. Its overall reduction in RSV-related medically attended infections was 60.5% versus placebo, with efficacy increasing alongside disease severity. The European Medicines Agency’s Committee for Medicinal Products for Human Use also issued a positive opinion for approval, signaling that this is becoming a global standard of care rather than a regional one. The difference between having zero options and having two competing monoclonal antibodies in the span of a few years is significant. However, neither drug protects against bacterial infections, fungal threats, or the many other pathogens that stalk premature infants in the NICU. They are targeted tools, not shields against everything.
Maternal Vaccination — Can Protection Start Before Birth?
Before a baby ever takes a breath, the mother’s immune system can begin arming it. Abrysvo, Pfizer’s RSV vaccine, was FDA-approved on August 21, 2023, for administration to pregnant individuals between 32 and 36 weeks gestational age. The vaccine works through maternal antibody transfer: the mother produces RSV-specific antibodies that cross the placenta and protect the infant from birth through approximately six months of age. For families weighing their options, Abrysvo offers a complementary strategy to the monoclonal antibodies given directly to infants after delivery. However, there are important limitations.
Abrysvo’s protection depends on successful placental antibody transfer, which means it works best when the baby remains in utero long enough for that transfer to occur. A mother who delivers at 28 weeks due to preterm labor may not have had sufficient time for antibodies to reach protective levels in the fetus, which is precisely the scenario where the infant is most vulnerable. In those cases, postnatal monoclonal antibodies like Beyfortus or Enflonsia become essential. The practical reality for many premature births is that maternal vaccination alone is not enough — it is one layer in what needs to be a multi-layered defense. Clinicians increasingly talk about these interventions not as alternatives but as a combined strategy, where the maternal vaccine provides a baseline and the infant antibody fills the gaps.
Rytvela — A Drug That Could Prevent Preterm Birth Itself
Preventing infection in a premature baby is critical, but preventing the premature birth altogether would be transformative. Rytvela, an allosteric modulator of the interleukin-1 receptor, represents a fundamentally different approach. Rather than treating infection after birth, it targets the inflammatory signaling — specifically IL-1β-driven inflammation — that triggers preterm labor in the first place. In preclinical mouse models published in The Journal of Immunology in February 2026, Rytvela reduced preterm birth rates by 40% and decreased infant mortality even when administered after the onset of preterm labor. What makes Rytvela especially noteworthy is what it does not do. Existing drugs that target IL-1β tend to suppress the immune system broadly, which creates obvious dangers for both the mother and fetus during a period when infection risk is already elevated.
Rytvela avoids this immunosuppressive trade-off, leaving the immune system intact while dampening the specific inflammatory pathway responsible for triggering early labor. In the same preclinical models, the current standard treatment for preterm labor, Nifedipine, failed to confer similar benefits. Rytvela also prevented inflammation-induced neonatal tissue injury and promoted neonatal development even when given after the inflammatory exposure had already begun — a finding that suggests a wider therapeutic window than expected. Researchers are finalizing preclinical work and preparing for human clinical trials. If Rytvela succeeds in humans, it could reduce the number of babies who need NICU-level infection protection in the first place, which would be a paradigm shift. But it remains an experimental drug, and the gap between promising mouse data and a working human therapy is historically where many candidates fail.
Inhaled GM-CSF — Training Newborn Lungs to Fight Bacterial Pneumonia
The lungs of a newborn, particularly a premature one, lack the specialized immune cells that adults rely on to fight bacterial invaders. Researchers at Washington University School of Medicine found that an inhalable form of GM-CSF (granulocyte-macrophage colony-stimulating factor) can promote the development of lung-resident macrophages — the immune cells responsible for clearing bacteria from the airways. In animal studies, adult mice that received neonatal GM-CSF inhalation were protected from pneumococcal pneumonia with no adverse effects on lung development. The findings were published in Science Advances in August 2019. The critical details matter here.
The drug must be given within the first day after birth and delivered directly to the lungs via inhalation. When researchers tried administering GM-CSF intravenously or subcutaneously, it did not work — those routes mobilized neutrophils in the bloodstream rather than building up the lung macrophage population that actually fights respiratory infection. This specificity of delivery is both a strength and a practical challenge. GM-CSF is already an FDA-approved drug used safely in previous clinical trials in premature infants for other indications, which shortens the regulatory path, but developing a reliable inhalation protocol for a one-day-old preterm infant with fragile lungs is no small engineering problem. The trade-off is clear: a targeted intervention with strong preclinical evidence, but one that demands precise timing and delivery in a chaotic clinical setting.
The Hidden Cost of Antibiotics in the NICU
Nearly all premature babies receive antibiotics in their first weeks of life to prevent early-onset sepsis, a potentially fatal bloodstream infection. This practice has saved countless lives, and no one is suggesting it should stop entirely. But recent research from Washington University has revealed that this early antibiotic treatment can have lasting harmful effects on the gut microbiome. Heavily treated preemies carried significantly more drug-resistant bacteria at 21 months of age compared with those who received less antibiotic exposure.
The implications extend beyond the gut: a disrupted microbiome in infancy has been linked in broader research to altered immune development, increased risk of allergic and autoimmune conditions, and — of particular relevance to readers of this site — potential effects on the gut-brain axis that are only beginning to be understood. There is also the direct toxicity concern. In October 2025, the FDA issued a warning that premature babies receiving lopinavir/ritonavir (Kaletra) oral solution for HIV prophylaxis at birth face a risk of serious heart, kidney, or breathing problems. This is a different class of drug than the antibiotics given for sepsis prevention, but it underscores a broader truth: the immature organs of a premature infant process medications differently than those of a full-term baby, and what is safe for one population may not be safe for another. The new generation of targeted monoclonal antibodies and immune-training approaches like inhaled GM-CSF represent an attempt to move away from broad pharmacological carpet-bombing toward precision interventions with fewer downstream consequences.
Why Neonatal Infection Protection Matters for Lifelong Brain Health
The connection between early-life infection and long-term neurological outcomes is one reason this topic belongs on a brain health site. Premature infants who survive serious infections in the NICU face elevated rates of neurodevelopmental impairment, including cognitive delays, cerebral palsy, and — in emerging longitudinal research — potential susceptibility to neurodegenerative conditions later in life.
The inflammatory cytokines unleashed during neonatal infection can cross the immature blood-brain barrier and damage developing white matter, the same tissue whose degradation defines many forms of dementia decades later. Rytvela’s ability to prevent inflammation-induced neonatal tissue injury in preclinical models is relevant here, as is the broader shift toward immune-targeted rather than antibiotic-heavy approaches. Every serious infection prevented in a premature infant is not just a crisis averted — it is a potential neuroprotective event with consequences that may not become visible for fifty or sixty years.
What Comes Next for Neonatal Infection Prevention
The field is moving from reactive to proactive. Two competing RSV monoclonal antibodies give clinicians and families choices that did not exist five years ago. Maternal vaccination adds a prenatal layer. Rytvela, if it succeeds in human trials, could reduce the preterm birth rate itself. And inhaled GM-CSF points toward a future where we can train a newborn’s immune system in its first hours rather than flooding it with antibiotics and hoping for the best.
None of these interventions alone is sufficient. RSV antibodies do not stop bacterial sepsis. Maternal vaccines depend on gestational timing. Rytvela is years from clinical availability. Inhaled GM-CSF requires a delivery method that does not yet exist for human neonates at scale. But taken together, they represent a genuine shift in how medicine thinks about protecting the most fragile patients — and by extension, the most fragile brains — at the moment of greatest vulnerability.
Conclusion
The question of which drug protects premature babies from infection at birth no longer has a single answer. Beyfortus and Enflonsia provide powerful, targeted RSV protection with hospitalization reductions exceeding 83%. Abrysvo offers a maternal vaccination route. Rytvela may eventually prevent preterm birth itself by interrupting the inflammatory cascade that causes it. Inhaled GM-CSF could one day prime neonatal lungs against bacterial pneumonia within hours of delivery.
Each addresses a different piece of the puzzle, and each carries its own limitations — from narrow pathogen coverage to preclinical-only evidence to demanding delivery logistics. For anyone invested in brain health across the lifespan, the neonatal period deserves attention. The infections that threaten premature infants are not just acute medical emergencies — they are events with potential neurological consequences that can unfold over decades. The drugs emerging to prevent these infections are, in a real sense, some of the earliest neuroprotective interventions available. Families with premature infants should talk with their neonatologist about RSV immunization timing, maternal vaccination eligibility, and what monitoring protocols are in place for antibiotic stewardship in the NICU. The science is moving fast, and the options available today are meaningfully better than those available even two years ago.
Frequently Asked Questions
Is Beyfortus or Enflonsia better for protecting premature babies against RSV?
Both are FDA-approved monoclonal antibodies with strong efficacy. Beyfortus showed 83.2% efficacy against RSV hospitalization in preterm infants, while Enflonsia demonstrated an 84.3% reduction in RSV hospitalizations. Enflonsia uses a single fixed dose regardless of weight, which may simplify administration. The choice between them is best made with a neonatologist based on availability, timing, and the individual infant’s risk profile.
Can a pregnant woman get the RSV vaccine and the baby still receive a monoclonal antibody?
Abrysvo is approved for pregnant individuals at 32 to 36 weeks gestational age, and infants can also receive Beyfortus or Enflonsia after birth. However, current clinical guidance generally recommends one approach or the other rather than both, depending on timing and circumstances. Parents should discuss the combined strategy with their obstetrician and pediatrician.
When will Rytvela be available for preventing preterm birth in humans?
As of early 2026, Rytvela remains in the preclinical stage. Researchers are finalizing animal studies and preparing for human clinical trials. Even optimistically, it would be several years before Rytvela could reach clinical availability, assuming it demonstrates safety and efficacy in human populations.
Are antibiotics still necessary for premature babies if these new drugs exist?
Yes. The new monoclonal antibodies target RSV specifically and do not protect against bacterial sepsis, which remains a leading threat to premature infants. Antibiotics are still the standard of care for preventing early-onset sepsis. However, growing evidence of lasting microbiome disruption and increased drug-resistant bacteria in antibiotic-treated preemies is driving research toward more targeted alternatives.
Does preventing neonatal infection actually reduce dementia risk later in life?
Direct causal evidence linking neonatal infection prevention to reduced dementia risk decades later does not yet exist. However, serious neonatal infections trigger inflammatory responses that can damage developing white matter in the brain, and white matter degradation is a hallmark of several forms of dementia. The biological plausibility is strong, even if the longitudinal data is still being gathered.
